Investigational New Drugs

, Volume 28, Issue 5, pp 554–560

An in vitro study, evaluating the effect of sunitinib and/or lapatinib on two glioma cell lines

  • Efstathia Giannopoulou
  • Konstantinos Dimitropoulos
  • Andreas A. Argyriou
  • Angelos K. Koutras
  • Fotinos Dimitrakopoulos
  • Haralabos P. Kalofonos
PRECLINICAL STUDIES

Summary

Aim We sought to assess the effect of sunitinib and lapatinib applied either alone or in combination, on U87 and M059K glioma cells. Methods Both cell lines were cultured as recommended by the manufacturer. Sunitinib and lapatinib were applied, either separately or in combination, in the cultured cells after cell attachment at doses of 10nM, 100nM, 1 μM and 10 μM. To determine whether the agents affect the proliferation of glioma cells, the 3-[4,5-dimethylthiazol-2-yl]-2,5 dimethyltetrazolium bromide assay was used. Apoptosis was detected using annexin V/propidium iodide detection assay, migration assay was performed in 24-well microchemotaxis chambers. The release of MMPs into the culture medium of U87 and M059K cells was measured by zymography. Results Both agents, administered either alone or in combination, decreased cell proliferation in a dose-dependent manner 48 h after their application in both cell lines. The inhibition of their combination was statistically different than the inhibition of each agent alone. Apoptosis was increased and migration of U87 and M059K cells was inhibited either by each agent alone or their combination. MMPs levels remained unaffected by the application of both agents in U87 cells. However, MMP-9 and MMP-2 levels were decreased 48 h after treatment of M059K cells with sunitinib either alone or in combination with lapatinib. Conclusion Sunitinib and/or lapatinib appear to exhibit significant effects on proliferation, apoptosis and migration of glioma cells. When applied alone, sunitinib appears to be a more potent inhibitor than lapatinib.

Keywords

Lapatinib Sunitinib Malignant glioma Proliferation Apoptosis Migration MMPs 

References

  1. 1.
    Argyriou AA, Antonacopoulou A, Iconomou G, Kalofonos HP (2009) Treatment options for malignant gliomas, emphasizing towards new molecularly targeted therapies. Crit Rev Oncol Hematol 69(3):199–210CrossRefPubMedGoogle Scholar
  2. 2.
    Omuro AM, Faivre S, Raymond E (2007) Lessons learned in the development of targeted therapy for malignant gliomas. Mol Cancer Ther 6(7):1909–1919CrossRefPubMedGoogle Scholar
  3. 3.
    Polyzos A (2008) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors. J Steroid Biochem Mol Biol 108(3–5):261–266CrossRefPubMedGoogle Scholar
  4. 4.
    Adams VR, Leggas M (2007) Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors. Clin Ther 29(7):1338–1353CrossRefPubMedGoogle Scholar
  5. 5.
    Abrams TJ, Murray LJ, Pesenti E, Holway VW, Colombo T, Lee LB, Cherrington JM, Pryer NK (2003) Preclinical evaluation of the tyrosine kinase inhibitor 5Ul1248 as a single agent and in combination with “standard of care” therapeutic agents for the treatment of breast cancer. Mol Cancer Ther 2:1011–1021PubMedGoogle Scholar
  6. 6.
    Cuneo KC, Geng L, Fu A, Orton D, Hallahan DE, Chakravarthy AB (2008) SU11248 (sunitinib) sensitizes pancreatic cancer to the cytotoxic effects of ionizing radiation. Int J Radiat Oncol Biol Phys 71(3):873–879PubMedGoogle Scholar
  7. 7.
    de Boüard S, Herlin P, Christensen JG, Lemoisson E, Gauduchon P, Raymond E, Guillamo JS (2007) Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma. Neuro Oncol 9(4):412–423CrossRefPubMedGoogle Scholar
  8. 8.
    Schueneman AJ, Himmelfarb E, Geng L, Tan J, Donnelly E, Mendel D, McMahon G, Hallahan DE (2003) SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res 63(14):4009–4016PubMedGoogle Scholar
  9. 9.
    Chu I, Blackwell K, Chen S, Slingerland J (2005) The Dual ErbB1/ErbB2 Inhibitor, Lapatinib (LAPATINIB), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res 65:18–25PubMedGoogle Scholar
  10. 10.
    Gregory C, Whang YE, McCall W, Fei X, Liu Y, Ponguta LA, French FS, Wilson EM, Shelton H (2005) Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth. Clin Cancer Res 11:1704–1712CrossRefPubMedGoogle Scholar
  11. 11.
    Blansfield JA, Caragacianu D, Alexander HR III, Tangrea MA, Morita SY, Lorang D, Schafer P et al (2008) Combining agents that target the tumor microenvironment improves the efficacy of anticancer therapy. Clin Cancer Res 14(1):270–280CrossRefPubMedGoogle Scholar
  12. 12.
    Giannopoulou E, Papadimitriou E (2003) Amifostine has antiangiogenic properties in vitro by changing the redox status of human endothelial cells. Free Rad Res 37(11):1191–1199CrossRefGoogle Scholar
  13. 13.
    Kuwada SK, Scaife CL, Kuang J, Li X, Wong RF, Florell SR, Coffey RJ, Gray PD (2004) Effects of trastuzumab on epidermal growth factor receptor-dependent and-independent human colon cancer cells. Int J Cancer 109:291–301CrossRefPubMedGoogle Scholar
  14. 14.
    Giannopoulou E, Antonacopoulou A, Floratou K, Papavassiliou A, Kalofonos H (2009) Dual targeting of EGFR and HER-2 in colon cancer cell lines. Cancer Chemother Pharmacol 63(6):973–981CrossRefPubMedGoogle Scholar
  15. 15.
    Fischel JL, Formento P, Milano G (2005) Epidermal growth factor receptor double targeting by a tyrosine kinase inhibitor (Iressa) and a monoclonal antibody (Cetuximab). Impact on cell growth and molecular factors. Br J Cancer 92(6):1063–1068CrossRefPubMedGoogle Scholar
  16. 16.
    Sathornsumetee S, Reardon DA, Desjardins A, Quinn JA, Vredenburgh JJ, Rich JN (2007) Molecularly targeted therapy for malignant glioma. Cancer 110(1):13–24CrossRefPubMedGoogle Scholar
  17. 17.
    Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86(3):353–364CrossRefPubMedGoogle Scholar
  18. 18.
    Zetser A, Bashenko Y, Miao HQ, Vlodavsky I, Ilan N (2003) Heparanase affects adhesive and tumorigenic potential of human glioma cells. Cancer Res 63(22):7733–7741PubMedGoogle Scholar
  19. 19.
    Gril B, Palmieri D, Bronder JL, Herring JM, Vega-Valle E, Feigenbaum L, Liewehr DJ et al (2008) Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J Natl Cancer Inst 100(15):1092–1103CrossRefPubMedGoogle Scholar
  20. 20.
    Xing W, Hamaguchi M (2007) Effects of SHIP-1 on MMP2 secretion and invasion of SR3Y1 cells. J Genet Genomics 34(4):285–293CrossRefPubMedGoogle Scholar
  21. 21.
    Westermark B, Heldin CH, Nistér M (1995) Platelet-derived growth factor in human glioma. Glia 15(3):257–263CrossRefPubMedGoogle Scholar
  22. 22.
    Mischel PS, Cloughesy TF (2003) Targeted molecular therapy of GBM. Brain Pathol 13(1):52–61PubMedCrossRefGoogle Scholar
  23. 23.
    Stommel JM, Kimmelman AC, Ying H et al (2007) Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318(5848):287–290CrossRefPubMedGoogle Scholar
  24. 24.
    Goudar RK, Shi Q, Hjelmeland MD, Keir ST, McLendon RE, Wikstrand CJ, Reese ED et al (2005) Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Mol Cancer Ther 4(1):101–112PubMedGoogle Scholar
  25. 25.
    Motzer RJ, Rini BI, Bukowski RM et al (2006) Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295:2516–2524CrossRefPubMedGoogle Scholar
  26. 26.
    Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115–124CrossRefPubMedGoogle Scholar
  27. 27.
    Koutras AK, Krikelis D, Alexandrou N, Starakis I, Kalofonos HP (2007) Brain metastasis in renal cell cancer responding to sunitinib. Anticancer Res 27(6C):4255–4257PubMedGoogle Scholar
  28. 28.
    Geyer CE, Forster J, Lindquist D et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733–2743CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Efstathia Giannopoulou
    • 1
  • Konstantinos Dimitropoulos
    • 1
  • Andreas A. Argyriou
    • 1
  • Angelos K. Koutras
    • 1
  • Fotinos Dimitrakopoulos
    • 1
  • Haralabos P. Kalofonos
    • 1
  1. 1.Clinical Oncology Laboratory, Division of Oncology, Department of MedicineUniversity Hospital of Patras, Patras Medical SchoolRionGreece

Personalised recommendations